- Home
- CATX vs NYXH Comparison
CATX vs NYXH Comparison
Compare CATX & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- NYXH
- Stock Information
- Founded
- CATX 1983
- NYXH 2009
- Country
- CATX United States
- NYXH Belgium
- Employees
- CATX N/A
- NYXH N/A
- Industry
- CATX Medical/Dental Instruments
- NYXH Medical/Dental Instruments
- Sector
- CATX Health Care
- NYXH Health Care
- Exchange
- CATX Nasdaq
- NYXH Nasdaq
- Market Cap
- CATX 239.0M
- NYXH 222.3M
- IPO Year
- CATX N/A
- NYXH 2021
- Fundamental
- Price
- CATX $3.44
- NYXH $7.75
- Analyst Decision
- CATX Strong Buy
- NYXH Strong Buy
- Analyst Count
- CATX 10
- NYXH 4
- Target Price
- CATX $13.00
- NYXH $14.50
- AVG Volume (30 Days)
- CATX 1.5M
- NYXH 76.5K
- Earning Date
- CATX 08-11-2025
- NYXH 08-05-2025
- Dividend Yield
- CATX N/A
- NYXH N/A
- EPS Growth
- CATX N/A
- NYXH N/A
- EPS
- CATX N/A
- NYXH N/A
- Revenue
- CATX $1,471,000.00
- NYXH $4,716,818.00
- Revenue This Year
- CATX N/A
- NYXH $323.07
- Revenue Next Year
- CATX N/A
- NYXH $204.30
- P/E Ratio
- CATX N/A
- NYXH N/A
- Revenue Growth
- CATX N/A
- NYXH N/A
- 52 Week Low
- CATX $1.60
- NYXH $5.55
- 52 Week High
- CATX $16.55
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- CATX 60.53
- NYXH 62.70
- Support Level
- CATX $2.96
- NYXH $7.45
- Resistance Level
- CATX $3.77
- NYXH $7.85
- Average True Range (ATR)
- CATX 0.41
- NYXH 0.27
- MACD
- CATX 0.02
- NYXH -0.02
- Stochastic Oscillator
- CATX 73.78
- NYXH 97.33
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.